Mankind Pharmaceuticals Ltd. and Glenmark Pharmaceuticals Ltd. have inked a sub-licensing agreement to co-market sodium glucose co-transporter-2 (SGLT2) inhibitor, Remogliflozin Etabonate (Remogliflozin) in India.
Under the agreement, Mankind will market the drug under its own trademark while Glenmark will manufacture and supply Remogliflozin to Mankind.
In April 2019, Glenmark received approval from the Drugs Controller General of India (DCGI) for Remogliflozin Etabonate after successfully completing Phase-3 clinical trials. During the trials Remogliflozin demonstrated good efficacy and safety profile in a head-to-head comparison against Dapagliflozin. Subsequently, Glenmark launched Remogliflozin indicated in the treatment of Type 2 diabetes mellitus in adults under the brand names ‘Remo’ and ‘Remozen’.
Remogliflozin has been launched at a breakthrough price that is significantly lower and cost-effective over other SGLT2 inhibitors available in the country. In fact, Remogliflozin is the only SGLT-2 inhibitor to be manufactured in India from an active pharmaceutical ingredient (API) to the formulation.
